AURORA, ON, Nov. 15 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX, FSE: "HBP") today announced position changes for Dr. Donald Segal and John Docherty. Effective immediately, the joint role of Chief Executive Officer and President formerly held by Dr. Segal will be separated whereby Dr. Segal will remain the Company's Chief Executive Officer and Mr. Docherty will assume the role of President.
"These changes are being made as we strive to expand our corporate initiatives, primarily in the U.S.A.," said Dr. Segal. "Moving forward, I am pleased to have John take on added responsibilities so that I may increasingly focus my time on growing our business by developing new financial, partnering and other strategic initiatives for the Company. John will concentrate on enhancing our public profile, overseeing our advancing clinical programs and managing our related day to day operations."
Dr. Segal and Mr. Docherty have a history of proven leadership with the Company. Dr. Segal is a founding partner, serves on the board of directors and had been Chief Executive Officer and President since 2004. Mr. Docherty joined the Company in 1999 with degrees in toxicology and pharmacology and a comprehensive background in pharmaceutical product and corporate development. At Helix, Mr. Docherty has been instrumental in developing the Company's lead product candidate, Topical Interferon Alpha-2b, in addition to supporting the Company's growing investor and media relations initiatives. Previously, Mr. Docherty served as Vice President, Corporate Development since 2002.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in
the field of cancer therapy. The Company is actively developing innovative
products for the prevention and treatment of cancer based on its
proprietary technologies. Helix's product development initiatives include
its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate.
|SOURCE Helix BioPharma Corp.|
Copyright©2007 PR Newswire.
All rights reserved